We develop nanosensor technology to accurately identify cacner at early stages. These nanosensors allow the non-invasive detection of disease biomarkers in various of biofluids such as cancer proteins, serum proteins and microRNA via optical detection, and they may interface with implantable devices.
The nanosensor technology could enable early detection of cancer and other diseases in people at high risk for the disease, or in successfully treated patients who have a high risk of recurrence. In people who are undergoing treatment, the sensors could signal immediately whether a biomarker is going up or down and — when needed — alert a doctor to switch to a different course of therapy. We are pursuing the translation of these sensor platforms from the laboratory to the clinic.
Z Yaari, Y Yang, E Apfelbaum, C Cupo, A Settle, Q Cullen, W Cai, K Long Roche, DA Levine, M Fleisher, LV Ramanathan, M Zheng, A Jagota, DA Heller*. ”A Perception-Based Machine-Perception Nanosensor Platform to Detect Cancer Biomarkers.” Science Advances (2021) In press.
J Budhathoki-Uprety, J Shah, JA Korsen, AE Wayne, TV Galassi, JR Cohen, JD Harvey, PV Jena, LV Ramanathan, EA Jaimes, DA Heller*. “Synthetic Molecular Recognition Nanosensor Paint for Microalbuminuria.” Nature Communications 10 (2019) 3605.
RM Williams, C Lee, TV Galassi, JD Harvey, R Leicher, M Sirenko, M Dorso, J Shah, N Olvera, F Dao, DA Levine,DA Heller*. “Non-Invasive Ovarian Cancer Biomarker Detection via an Optical Nanosensor Implant.” Science Advances 4 (2018) eaaq1090.
JD Harvey, PV Jena, HA Baker, GH Zerze, RM Williams, TV Galassi, D Roxbury, J Mittal, DA Heller: “A Carbon Nanotube Reporter of miRNA Hybridization Events In Vivo.” Nature Biomedical Engineering 1 (2017) 0041